Weekly Digest – June 2024 Weekly Digest – June 2024 12 June 2024: OBI Pharma Announces Phase 1/2 Study Initiation for OBI-992, a TROP2-Targeted Antibody-Drug Conjugate (ADC) for Cancer Therapy OBI Pharma has initiated a Phase 1/2 clinical trial for […]
Contact:
info@ciscientists.com
+1-908-212-7484
Optimal Dose
For a subscription, please provide your email id